priceline.com Incorporated (NASDAQ:PCLN): Benchmark Co. raised its estimates and price target for Priceline.com citing favorable trends in the hotel industry and the company’s increasing scale in emerging markets. The firm keeps a Buy rating on the stock.
ViroPharma Inc. (NASDAQ:VPHM): Leerink lowered its price target for ViroPharma shares to reflect a reduction in Vancocin cash flow estimates after the FDA approved three generic versions of the drug. The firm expects ViroPharma to acquire additional near-commercial stage products since the company is barely profitable without Vancocin at current spending.
F5 Networks, Inc. (NASDAQ:FFIV): William Blair said its channel checks indicate F5 Networks aggressively pushed to close deals in North America at the end of the quarter, which is a change from the previous two quarters, where the firm’s checks indicated backlog builds. William Blair attributes slower close cycles from the fragile economic recovery, and thinks F5 could report a lack of revenue upside in Q2, which the firm feels could disappoint many investors. However, William Blair added that its checks indicated F5 has generally strong pipelines and continued momentum in module sales. William Blair keeps an Outperform rating on shares of F5.
Costamare Inc. (NYSE:CMRE): Morgan Stanley’s checks indicate large container vessel rates are recovering. The firm believes Costamare shares have a floor given its yield and should move higher. Shares are Overweight rated.
Forest Laboratories Inc. (NYSE:FRX): Credit Suisse said shares of FOrest Labs are cheap and recommends buying the stock if there is any weakness surrounding 2013 guidance on next week’s update. The firm said Forest will be launching 4 products over the next 15 months and reiterates its Outperform rating and $44 price target.
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.